SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

PURPOSE: CHD1 deletions and SPOP mutations frequently cooccur in prostate cancer with lower frequencies reported in castration-resistant prostate cancer (CRPC). We monitored CHD1 expression during disease progression and assessed the molecular and clinical characteristics of CHD1 -deleted/SPOP-mutat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Boysen, Gunther, Rodrigues, Daniel N., Rescigno, Pasquale, Seed, George, Dolling, David, Riisnaes, Ruth, Crespo, Mateus, Zafeiriou, Zafeiris, Sumanasuriya, Semini, Bianchini, Diletta, Hunt, Joanne, Moloney, Deirdre, Perez-Lopez, Raquel, Tunariu, Nina, Miranda, Susana, Figueiredo, Inês, Ferreira, Ana, Christova, Rossitza, Gil, Veronica, Aziz, Sara, Bertan, Claudia, de Oliveira, Flavia M., Atkin, Mark, Clarke, Matthew, Goodall, Jane, Sharp, Adam, MacDonald, Theresa, Rubin, Mark A., Yuan, Wei, Barbieri, Christopher E., Carreira, Suzanne, Mateo, Joaquin, de Bono, Johann S.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6830304/
https://ncbi.nlm.nih.gov/pubmed/30068710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0937
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars